Device Trial Radar · NCT06888687
Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Actual
Start
May 12, 2025
Primary completion
Nov 28, 2026
Study completion Nov 28, 2026
Sponsor
- Lead sponsor
- Australian Catholic UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Abbott Diabetes Care; University of Adelaide; The University of Queensland; Monash University; University of Melbourne; Deakin University
- First posted
- Mar 21, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.
Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Continuous Glucose Measurement
- Dietary Modification
Interventions
Dietetic supportBehavioral
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence.
Continuous glucose monitoringDevice
Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor. Nine sensors will be provided for the 6-month period, for 3 months of continuous use and 3 months of intermittent (2 weeks on - 2 weeks off) use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: baseline, 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Australian Catholic University
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.